How to treat adverse reactions caused by capmatinib (Tabrecta)?

Introduction: Capmatinib (Tabrecta) is indicated for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have mutations that lead to mesenchymal epithelial transition (MET) exon 14 skipping, which requires an FDA-approved test to detect.

Adverse reactions caused by Tabrecta

During the course of taking Tabrecta, some adverse reactions may occur, including but not limited to the following.

1. Edema: including peripheral swelling and fluid overload, it is one of the most common adverse reactions.

2. Nausea and vomiting: Patients taking capmatinib may experience these digestive discomforts.

3. Musculoskeletal pain: may appear in different parts of the body.

4. Fatigue: Weakness or fatigue are also common adverse reactions.

5. Dyspnea and cough: It may be related to interstitial lung disease and pneumonia. It is a potentially serious adverse reaction and requires close attention.

6. Decreased appetite: It may affect the patient's nutritional status and overall health.

Patients should closely monitor these adverse reactions while using capmatinib, and contact their doctor promptly if serious reactions occur. Corresponding treatment will be carried out according to the severity of the adverse reactions, which may require dose adjustment or discontinuation.

How to treat the adverse reactions of Tabrecta

The treatment of adverse reactions of Tabrecta mainly determines the corresponding treatment measures based on the type and severity of the adverse reactions. You can refer to the following treatment measures.

1. Edema: It can be treated by adjusting the dosage or using diuretics as directed by the doctor.

2. Nausea and vomiting: This can be improved by using anti-nausea drugs and changing dietary habits.

3. Diarrhea: You may need to use anti-diarrhea drugs and pay attention to replenishing water and electrolytes.

4. Loss of appetite: Nutritional support and adjustment of diet plan may be needed to help patients maintain weight.

5. Fatigue: Patients are advised to maintain adequate rest and may need to adjust daily activities and treatment plans.

Patients should closely monitor these adverse reactions while taking capmatinib and contact their doctor promptly if occur.

Special population use of capmatinib

1. Elderly patients: Capmatinib has a good safety profile in elderly patients, with a low incidence of treatment-related adverse reactions, most of which are mild to moderate.

2. Pregnant and lactating women: There is currently no safety data on capmatinib for pregnant and lactating women, so it is recommended that it should be contraindicated by pregnant and lactating women.

3. Children and Adolescents: The safety and effectiveness of capmatinib in children and adolescents have not been determined.

When using capmatinib, doctors will develop a personalized treatment plan based on the patient's specific conditions, closely monitor the patient's response and potential adverse reactions during the treatment process, and make dose adjustments or discontinuation if necessary.